Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other financing activities (2016 - 2020)

Agios Pharmaceuticals' Other financing activities history spans 5 years, with the latest figure at $250.5 million for Q2 2020.

  • For Q2 2020, Other financing activities changed N/A year-over-year to $250.5 million; the TTM value through Mar 2021 reached $250.5 million, changed N/A, while the annual FY2020 figure was $250.5 million, N/A changed from the prior year.
  • Other financing activities reached $250.5 million in Q2 2020 per AGIO's latest filing, up from $203000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $250.5 million in Q2 2020 to a low of -$727000.0 in Q4 2017.
  • Average Other financing activities over 4 years is $27.8 million, with a median of $124000.0 recorded in 2016.
  • Peak YoY movement for Other financing activities: tumbled 785.85% in 2017, then soared 199.51% in 2018.
  • A 4-year view of Other financing activities shows it stood at $106000.0 in 2016, then crashed by 785.85% to -$727000.0 in 2017, then soared by 127.92% to $203000.0 in 2018, then surged by 123317.24% to $250.5 million in 2020.
  • Per Business Quant, the three most recent readings for AGIO's Other financing activities are $250.5 million (Q2 2020), $203000.0 (Q2 2018), and $188000.0 (Q1 2018).